Drug Trial Radar · NCT05963997
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Oct 9, 2023
Primary completion
Mar 6, 2026
Study completion Mar 6, 2026
Sponsor
- Lead sponsor
- Carrick Therapeutics LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Berlin-Chemie AG Menarini Group
- First posted
- Jul 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an international, multisite, open-label, Phase 1b/2 study, to confirm safety and efficacy of samuraciclib in combination with elacestrant in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.
Conditions
- Metastatic Breast Cancer
- Locally Advanced Breast Cancer
- Breast Cancer
Interventions
SamuraciclibDrug
Samuraciclib capsules by mouth once a day
Elacestrant DihydrochlorideDrug
Elacestrant tablets by mouth once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b (Dose-finding)Time frame: From the date of first dose of any study intervention (Day 1 Cycle 1) and through 28 days after the last dose of any study intervention
- Phase 2 (Expansion)Time frame: From the date of first dose of any study intervention (Cycle 1 Day 1) until the first documentation of disease progression, death, withdrawal of consent, or start of new anticancer therapy (assessed up to week 48)
Locations
23 sites in 4 countries. Site status is shown where the registry gives one.
Site 38 - Northwestern University, Feinberg School of Medicine, Northwestern University
Chicago, Illinois
Site 42 - Dana-Farber Cancer Institute, EDDC
Boston, Massachusetts
Site 35 - Cleveland Clinic, Taussig Cancer Institute
Cleveland, Ohio
Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology
San Antonio, Texas
Site 32 - Swedish Medical Center, Swedish Cancer Institute (SCI),Cherry Hill Campus
Seattle, Washington
Site 81 - Bergonie unicancer, Nouvelle-Aquitaine, L'Institut Bergonie
Bordeaux, France
Site 80 - Centre Jean Bernard, Clinique Victor Hugo
Le Mans, France
Site 83 - Institut Paoli Calmettes (IPC)
Marseille, France
Site 85 - Institut Curie
Paris, France
Site 82 - Institut de Cancerologie de Ouest (ICO)
Saint-Herblain, France
Site 65 - Complexo Hospitalario Universitario A Coruña
A Coruña, Spain
Site 64 - Hospital Clinic de Barcelona (Hospital Clinic i Provincial)
Barcelona, Spain
Site 68 -Hospital Universitario Vall d'Hebron
Barcelona, Spain
Site 61 - Institut Catala d'Oncologia (ICO), Hospital Duran i Reynals Location
L'Hospitalet de Llobregat, Spain
Site 62 - Universidad de Navarra, Clinica Universidad de Navarra (CUN)
Madrid, Spain
Site 63 - South Texas Accelerated Research Therapeutics, CIOCC, Hospital Madrid Norte-Sanchinarro
Madrid, Spain
Site 66 - Hospital Clinico San Carlos
Madrid, Spain
Site 69 - Universidad de Navarra - Clinica Universidad de Navarra (CUN)
Pamplona, Spain
Site 60 - NEXT Oncology EU Hospital Universitario Quiron Salud Madrid
Pozuelo de Alarcón, Spain
Site 67 - Universidad de Sevilla, Hospital Universitario Virgen Macarena
Seville, Spain
Site 12 - Belfast City Hospital
Belfast, United Kingdom
Site 4 - The Christie NHS Foundation Trust
Manchester, United Kingdom
Site 2 - Oxford University Hospitals NHS Trust - Churchill Hospital
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.